Understanding the Changing Treatment Landscape of Severe Asthma
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Overview:
Activity Release Date: November 28, 2023
Activity Expiration Date: November 28, 2024
Estimated time to complete Activity: 60 minutes
Provider Statement
This activity is provided by National Jewish Health.
Support Statement
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Target Audience
Physicians, nurse practitioners and physician assistants in pulmonology and allergy.
Program Description
The discovery of the mechanisms of type 2 (T2) inflammation in asthma gave rise to biologic therapies that have dramatically expanded treatment options for patients with moderate-to-severe eosinophilic or allergic asthma. Newly approved and emerging therapies that target the epithelial alarmins represent an important opportunity to improve outcomes for patients with a broad range of asthma phenotypes.
In this activity, expert faculty will provide insights into the new paradigm of treatments and how to manage the complexity of severe asthma treatment. This program will focus on the role of epithelial alarmins in the inflammatory cascade of asthma, and connecting clinical characteristics to patients’ biomarkers for treatment. Topics include: current challenges in severe asthma management; the pathophysiology of severe asthma; targets for current and emerging treatments; and selecting treatments based on patient phenotypes.
Learning Objectives
- Explain the mechanisms of action of biologic therapies for severe asthma and key features of severe asthma that are targets for treatment.
- Describe the role of the respiratory epithelium in asthma and the relationship to T2 and non-T2 airway inflammation.
- Evaluate the emerging data for new and emerging therapies that target the epithelial alarmins.
- Connect clinical characteristics and phenotypes to the targeted treatment.
Faculty
Rohit K. Katial, MD, FAAAAI, FACAAI, FACP
Professor of Medicine
Associate Vice President of Education
Director, Center for Clinical Immunology
Irene J. and Dr. Abraham E. Goldminz, Chair in Immunology and Respiratory Medicine
National Jewish Health
Denver, Colorado
Eileen Wang, MD, MPH
Associate Professor
Division of Allergy & Clinical Immunology
Department of Medicine
National Jewish Health
Denver, Colorado
Michael E. Wechsler, MD, MMSc
Director, The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, Colorado
Accreditation
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive CME credit, participants must complete the pre-assessment, view the activity content, and complete the post-assessment and program evaluation. Participants must get 3 out of 4 answers correct on the post-assessment. A certificate will be distributed via email once the activity is complete. In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation. All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
How to Participate in this Activity and Obtain CME Credit
Conflicts of Interest Disclosure Policy
Faculty reports the following relationship(s)
Rohit Katial, MD
- Speaker: AstraZeneca, Genentech
- Advisory board: AstraZeneca and GlaxoSmithKline
- Investigator: AstraZeneca, Genentech, GlaxoSmithKline, and Sanofi
- Advisory board/Consultant: Amgen, Areteia Therapeutic, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Eli Lilly, GlaxoSmithKline, Incyte, Kinaset, Merck, Novartis, Phylaxis, Pulmatrix, Rapt Therapeutics, Regeneron, Restorbio, Roche/Genentech, Sanofi/Genzyme, Tetherex Pharmaceuticals, Teva, and Upstream Bio
- Speaker: Amgen, AstraZeneca, GlaxoSmithKline, Sanofi/Genzyme, and Regeneron
Planners and reviewers report the following relationship(s)
Harold A. Nelson, MDThe following planners/reviewers declare that they do not have any relevant financial relationships:
Elyce Bowron, MEd; Meghan Brenner, MA; Andrea Harshman, MHA; and Michael P. Mohning, MD
Unlabeled and Investigational Usage
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer Statement
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming. If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities. https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Contact proed@njhealth.org with any questions about the accreditation of this program.
Privacy Policy
CME Questions?